Introduction
Myelofibrosis is usually associated with myeloproliferative disorders, including chronic granulocytic leukemia, agnogenic myeloid metaplasia, polycythemia vera and megakaryocytic leukemia (1) . Secondary myelofibrosis is usually seen in patients with hematological malignancies, secondary to chemotherapy or radiotherapy (2) . Involvement of fibrosis of the bone marrow in the cases of primary MDSnot associated with previous chemotherapy or radiotherapy has been recently reported by Sultan et al (3) , Pagliuca et al (4) , LambertenghiDeliliers et al (5) , and others (6-13). The cause of the association of myelofibrosis and primary MDSremains to be determined. However, the significance of this complication deserves attention from the standpoint of the clinical diversity of MDS and the relating factors responsible for the pathogenesis of fibrosis in the field ofhematopoiesis. Wepresent three cases of primary MDSwhich were associated with myelofibrosis.
Case Report
Profiles of the patients are shown in Table 1 . The peripheral blood counts revealed various degrees of pancytopenia. The bone marrow revealed various grades ofcellularity, from normoto hypercellular marrowwith various types of dysplastic cells in the trilineage components. Thecytogenetic abnormalities or rearrangements of the oncogenes studied (N-ras, Ha-ras and Kiras) in the peripheral blood or bone marrow cells did not reveal abnormalities in any of the patients. No hepatosplenomegaly was seen in any of the patients on admission which was confirmed by echography or computed tomography. The bone marrow aspiration became dry tap in two patients (patients 1 and 2) at 2 or 3 months after admission, and was dry tap in patient 3 on admission. The bone marrowbiopsy specimens of these patients revealed various grades of increased reticulin fibers, stained with Gomori' s silver impregnation for reticulin fibers ( Fig. la-c) . The increase in megakaryocytes was observed in patient 3 ( Fig. lc) , and was not observed in the other patients. Patient 1 was treated by administration ofmetenolone, resulting in complete hematological remission which has lasted until present. Patients 2 and 3 were administered granulocytemacrophage colony-stimulating factor (GM-CSF). Patient 2 did not respond to this therapy, and an increasing numberof leukocytes was observed in patient 3; they died of cerebral hemorrhage 7 and 2 months after admission, respectively.
Autopsy findings of patient 3 revealed marked hepatosplenomegaly and microscopic infiltration of the blood cells indicating extramedullary hematopoiesis (Fig. 2a, b ).
Discussion
Myelofibrosis is arelatively rare finding in primary MDS (3-1 3) . However, in one report, an increase in reticulin fibers was seen in 65%ofMDScases, although it was not clarified whether these cases consisted solely of primary MDSor also contained cases of secondary MDS(6). The acute progressive fatal course of MDSassociated with myelofibrosis had been first reported as acute myelodysplasia with myelofibrosis by Sultan et al (3) . However, Pagliuca et al (4) reported a relatively longer survival. In general, the presence of myelofibrosis seems to confer a poor prognosis, although the survival rates are still related to the French-American-British (FAB) subtype (longer survival in patients with refractory anemia and chronic myelomonocytic leukemia compared with those of refractory anemia with excess of blasts). Many of the MDSpatients with myelofibrosis had cytogenetic abnormalities and a significantly shorter survival than those without myelofibrosis (12). Indeed, one of the present patients (patient 1 ) responded to the administration of metenolone and is still alive after more than 4 years. However, our other two patients died of hemorrhagiccomplications soon after admission.
Patient 3 of the present report might need the differential diagnosis from malignant fibrosis. These were formerly called malignant myelosclerosis ( 14, 1 5), acute myelofibrosis ( 16), or acute megakaryocytic myelofibrosis (17) . Methods of phenotyping megakaryoblasts indicated that these cases were variants of AML,rather than myelofibrosis, and had been designated as acute megakaryoblastic leukemia, referred to as M7 by the FAB classification (18, 19) . Furthermore, some
MDSpatients with myelofibrosis eventually develop acute megakaryoblastic leukemia (9, 1 2). Our case was different from those in that the bone marrowbiopsy and autopsy specimens revealed mainly fibrosis, and infiltration by immature megakaryocytes was not evident. Agnogenic myeloid metaplasia was also denied in this patient by the rapid clinical course, and by the absence ofhepatosplenomegaly and leukoerythroblastosis at the initial diagnosis (20) . The pathogenesis of the complication of myelofibrosis in MDSremains to be elucidated. A polypeptide growth factor capable of inducing fibroblast proliferation and collagen synthesis isolated from human platelets including platelet-derived growth factor (21) and transforming growth factor beta (22) could be responsible for the formation of myelofibrosis; further increased numbersof megakaryocyteswereobserved in most of the reported cases in the bone marrow biopsy specimens (4).
The multipotential stem cell origin of the pathogenesis of MDS might accompanymyelofibrosis as in other myeloproliferative disorders (1). However, in our patients, an increase in megakaryocytes was observed only in patient 3. The increasing numbers of such case reports indicate that primary MDSwith myelofibrosis represents a distinct clinical entity, and should be classified as a subgroup ofMDS, or should be considered as an addendum. The association ofextramedullary hematopoiesis in cases of MDSwith myelofibrosis has been recently reported (10). In those cases, the location of hematopoiesis was switched to extramedullary sites by the ribrosis of the bone marrow. The marked extramedullary hematopoiesis observed in our patient 3 might also suggest the effect of GM-CSFin enhancing extramedullary hematopoiesis.
